DNA repair is essential to prevent the cytotoxic or mutagenic effects of various types of DNA lesions, which are sensed by distinct pathways to recruit repair factors specific to the damage type. Although biochemical mechanisms for repairing several forms of genomic insults are well understood, the upstream signalling pathways that trigger repair are established for only certain types of damage, such as double-stranded breaks and interstrand crosslinks [1] [2] [3] . Understanding the upstream signalling events that mediate recognition and repair of DNA alkylation damage is particularly important, since alkylation chemotherapy is one of the most widely used systemic modalities for cancer treatment and because environmental chemicals may trigger DNA alkylation 4-6 . Here we demonstrate that human cells have a previously unrecognized signalling mechanism for sensing damage induced by alkylation. We find that the alkylation repair complex ASCC (activating signal cointegrator complex) 7 relocalizes to distinct nuclear foci specifically upon exposure of cells to alkylating agents. These foci associate with alkylated nucleotides, and coincide spatially with elongating RNA polymerase II and splicing components. Proper recruitment of the repair complex requires recognition of K63-linked polyubiquitin by the CUE (coupling of ubiquitin conjugation to ER degradation) domain of the subunit ASCC2. Loss of this subunit impedes alkylation adduct repair kinetics and increases sensitivity to alkylating agents, but not other forms of DNA damage. We identify RING finger protein 113A (RNF113A) as the E3 ligase responsible for upstream ubiquitin signalling in the ASCC pathway. Cells from patients with X-linked trichothiodystrophy, which harbour a mutation in RNF113A, are defective in ASCC foci formation and are hypersensitive to alkylating agents. Together, our work reveals a previously unrecognized ubiquitin-dependent pathway induced specifically to repair alkylation damage, shedding light on the molecular mechanism of X-linked trichothiodystrophy.
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A crucial first step in DNA repair involves the recognition of the damage, which in turn activates signalling pathways that recruit effectors and resolve the lesion. However, whether this 'sensortransducer-mediator' model is generally applicable to pathways dedicated to repairing each distinct type of DNA lesion, such as alkylated lesions, remains unknown.
Previous studies established that the dealkylating enzyme ALKBH3 functions in concert with the ASCC helicase complex 7 . We tested the subcellular localization of the catalytic subunit ASCC3 upon exposure to various DNA damaging agents. Endogenous ASCC3 formed nuclear foci upon treatment of U2OS cells with the alkylating agent methyl methanesulfonate (MMS; Fig. 1a ). Knockout of ASCC3 abrogated these foci (Extended Data Fig. 1a, b) . Strikingly, other types of DNA damaging agents did not significantly induce ASCC3 foci (Fig. 1a, b and Extended Data Fig. 1c ), although these genotoxins induced pH2A.X foci, indicative of DNA damage. ASCC3 foci were also observed with other alkylating agents used clinically in the treatment of various tumours 8 (Extended Data Fig. 1d ). The ASCC complex subunit ASCC2 also formed foci specifically after treatment with MMS (Extended Data Fig. 1e ). These foci were largely limited to G1/early S-phase of the cell cycle (Extended Data Fig. 2a ). Consistent with their known physical association 7, 9 , haemagglutinin (HA)-ASCC2 co-localized with ASCC3 upon MMS treatment, as did the dealkylase ALKBH3 (Extended Data Fig. 2b ). To ascertain that the ASCC complex is recruited to regions of the nucleus that have alkylation damage, we performed a proximity ligation assay (PLA). We found that a specific nuclear PLA signal between m 1 A and ASCC3 is induced upon MMS damage ( Fig. 1c  and Extended Data Fig. 2c ). The dealkylase ALKBH2 also formed foci that co-localized partly with ASCC3 (Extended Data Fig. 2d, e) . Conversely, two other alkylation repair factors, methylguanine methyltransferase and alkyladenine glycosylase, showed minimal co-localization with ASCC3 (Extended Data Fig. 2d, e) .
ASCC foci did not co-localize with pH2A.X or 53BP1, demonstrating that they are distinct from double-stranded break-induced foci (Extended Data Fig. 3a) . These foci were also distinct from GFP-PCNA or BMI-1 (Extended Data Fig. 3b ). We took an unbiased proteomic approach to identify the factors associated with ASCC foci in response to alkylation damage using tandem affinity purification (TAP) (Extended Data Fig. 3c ). Mass spectrometric analysis of ASCC2-associated proteins revealed the constitutive association of ASCC3 and ASCC1 (Supplementary Table 1 ). ASCC2 also associated with many spliceosome components and basal transcription factors (Extended Data Fig. 3d and Supplementary Table 1 ). These factors, including BRR2, PRP8, and TFII-I, had two-to threefold higher total peptide numbers from cells exposed to MMS, suggesting an increased association with the ASCC complex in response to alkylation-induced damage. Focused immunofluorescence studies revealed that ASCC components co-localized with BRR2 and PRP8 upon alkylation damage (Fig. 1d, e) . Furthermore, ASCC foci co-localized with elongating (Ser2-phosphorylated) RNA polymerase II, but not other transcriptionassociated nuclear bodies, such as paraspeckles (Extended Data Fig. 3e, f) . Consistently, RNase treatment before processing for immunofluorescence significantly reduced ASCC3 foci formation (Extended Data  Fig. 3g ). Purified ASCC3 bound to ssRNA in vitro (Extended Data  Fig. 3h ). Chemical inhibition of transcription or splicing during alkylation damage also reduced ASCC3 foci (Extended Data  Fig. 4a, b) . Although recruitment of certain repair complexes is dependent on specific upstream signalling kinases 1-3 , inhibition of ATM (ataxiatelangiectasia mutated) moderately increased ASCC3 foci formation, and ATR (ataxia-telangiectasia and Rad3 related) inhibition had no impact (Extended Data Fig. 4c ). We found that HA-ASCC2 foci colocalized with polyubiquitin, suggesting that ubiquitin signalling may recruit this repair complex (Extended Data Fig. 4d) . Analysis of the ASCC2 protein sequence revealed a highly conserved CUE domain (residues 467-509), which belongs to the ubiquitin-binding domain superfamily 10 ( Fig. 2a) . A deposited but unpublished NMR structure of the ASCC2 CUE domain (Protein Data Bank (PDB) accession number 2DI0) was used to model its interaction with ubiquitin compared with another CUE domain from Vps9 (Fig. 2b) . Whereas Vps9 CUE binds to ubiquitin as a dimer 11 , our model predicts ubiquitin binding by a monomeric form of the ASCC2 CUE. His-tagged ASCC2 (Extended Data Fig. 4e ) bound K63-but not K48-linked ubiquitin chains (Fig. 2c) . Furthermore, ASCC2 co-localized with K63-but not K48-linked ubiquitin foci upon MMS damage (Extended Data Fig. 4f ). The minimal domain of ASCC2 for ubiquitin binding in vitro comprised residues 457-525 (Extended Data Fig. 5a-d) . However, the presence of an additional conserved region adjacent to the CUE domain was necessary for specific binding to K63-linked ubiquitin (Extended Data Fig. 5a-d) .
We introduced point mutations in the ASCC2 CUE domain at residues predicted to be critical for ubiquitin recognition (Extended Data Fig. 5e ). The mutations L506A (ASCC2(L506A)) and L478A-479A (ASCC2(L478A-479A)) abrogated ubiquitin binding in vitro, while another, P498A (ASCC2(P498A)), bound to K63-Ub similar to wildtype ASCC2 (Extended Data Fig. 5f ). Isothermal titration calorimetry experiments demonstrated that wild-type ASCC2 bound K63-linked di-ubiquitin chains with a dissociation constant (K d ) of 10.1 μ M, which is similar to other CUE domains 12 . By contrast, the ASCC2(L506A) mutant showed no detectable binding (Fig. 2d) . Notably, ASCC2 mutants that abrogate ubiquitin binding showed significantly reduced foci formation upon MMS treatment (Fig. 2e) .
We reasoned that ASCC2 acts as an intermediary subunit to recruit other components of the ASCC-ALKBH3 complex. Thus, we generated ASCC2 knockout cells using CRISPR-Cas9 (Extended Data Fig. 6a ). Two independent ASCC2 knockout clones showed a significant reduction in ASCC3 foci formation upon MMS treatment (Fig. 3a, b ). This reduction was not due to a change in the population of cells in G1 (Extended Data Fig. 6b ). HA-ALKBH3 and HA-ALKBH2 foci were also diminished in the mutant cells, albeit more modestly for HA-ALKBH2 ( Fig. 3c and Extended Data Fig. 6c ). Consistent with a role in the recruitment of these factors, ASCC2-deficient PC-3 cells were hypersensitive to MMS, but not to camptothecin or bleomycin (Extended Data Fig. 6d-h ). DNA-alkylated lesion repair kinetics were also slower in ASCC2 knockout cells (Fig. 3d) .
Next, we reconstituted ASCC2 knockout cells with wild-type and mutant versions of ASCC2. Wild-type ASCC2, but not the L506A CUE mutant, restored MMS-induced ASCC3 and HA-ALKBH3 foci formation (Fig. 3e , f and Extended Data Figs 6i, j and 7a). Similarly, wild-type, but not ASCC2(L506A), rescued MMS sensitivity of ASCC2 knockout cells (Extended Data Fig. 6k ). Wild-type and ASCC2(L506A) equally co-immunoprecipitated ASCC3 (Extended Data Fig. 7b ). Indeed, His-ASCC3 bound to immobilized Flag-ASCC2 and Flag-ALKBH3, although binding with ALKBH3 seemed weaker (Extended Data Fig. 7c ). Deletion of the ASCC3 N terminus abrogated its ability to bind ASCC2, while retaining ALKBH3 binding (Extended Data Fig. 7d ). Conversely, ASCC2 did not interact with recombinant ALKBH3 (Extended Data Fig. 7e) . ASCC2 therefore appears to bridge ASCC3 and K63-linked ubiquitin chains, while ALKBH3 is indirectly recruited by ASCC2 through its interaction with ASCC3 (Extended Data Fig. 7f ).
UBC13, a major E2 ubiquitin ligase responsible for formation of K63-linked ubiquitin chains, has been implicated in DNA damage response pathways [13] [14] [15] . Knockdown of UBC13 reduced 53BP1 foci, and attenuated MMS-induced HA-ASCC2 foci (Extended Data Fig. 8a-c) . However, knockdown of RNF8 or RNF168, two E3 ligases involved in double-stranded break repair 1 , did not affect HA-ASCC2 foci formation (data not shown), suggesting that a distinct E3 ligase functions in the alkylation pathway. To identify this E3 ligase, we performed a screen using a custom library of short hairpin RNAs (shRNAs) that target UBC13-interacting E3 ligases or other ligases implicated in DNA repair (Supplementary Table 2 ). The screen identified RNF113A as a potential candidate, with three distinct shRNAs reducing HA-ASCC2 foci to UBC13 knockdown levels (Extended Data Fig. 8d ). We confirmed that these shRNAs attenuated both RNF113A protein levels and HA-ASCC2 foci formation (Extended Data Fig. 8e and Fig. 4a) . Importantly, MMS-induced ASCC2 foci co-localized with RNF113A (Extended Data Fig. 8f ). In the absence of damage, RNF113A co-localized with PRP8 and BRR2 (Extended Data Fig. 8g) , consistent with previous studies suggesting that it nominally serves as a spliceosome component 16 . We purified Flag-tagged RNF113A from HeLa-S cells to analyse its E3 ligase activity (Extended Data Fig. 9a ). RNF113A exhibited robust E3 activity in vitro, which was markedly reduced with a RING-finger point mutation (I264A; Extended Data Fig. 9b ). Use of K63R ubiquitin abrogated chain elongation, suggesting that RNF113A may function to promote the E2 activity of UBC13 (Fig. 4b) . A recent study identified a nonsense mutation (Q301* ) in RNF113A in two related individuals suffering from X-linked trichothiodystrophy 17 (X-TTD). Although most cells from patients with TTD are hypersensitive to ultraviolet damage, X-TTD cells do not have this phenotype 17 . Lymphoblastoid cell lines obtained from these two patients were hypersensitive to MMS, as was an RNF113A knockdown cell line (Extended Data Fig. 9c, d ). Strikingly, X-TTD cells had significantly reduced ASCC3 foci formation ( Fig. 4c and Extended Data Fig. 9e ). Reconstitution of these patient cells with wild-type RNF113A rescued ASCC3 foci formation, while the I264A mutant gave a partial rescue, possibly because of the small degree of remaining E3 ligase activity. Loss of TTDN1, which is also associated with TTD 18 , also reduced ASCC3 foci formation (Extended Data Fig.  9f ).
To uncover the relevant RNF113A substrate, we combined our initial proteomics screen (Extended Data Fig. 3d ) with a second screen for proteins that interact preferentially with wild-type ASCC2 relative to ASCC2(L506A) (Fig. 4D and Supplementary Table 3 ). Of the remaining putative ubiquitinated substrates, eight have been shown to be ubiquitinated by UBC13 (ref. 15) . Of these, BRR2 was the most obvious candidate, as it co-localized with RNF113A and ASCC components. Indeed, BRR2 co-immunoprecipitated with RNF113A in a manner dependent upon the N-terminal domain of RNF113A (Fig. 4e) . Deletion analysis revealed that the RNF113A N terminus was also critical for its co-localization with PRP8 (Extended Data Fig. 10a, b) . Ubiquitin conjugation of BRR2 was markedly reduced upon loss of RNF113A (Extended Data Fig. 10c ). Furthermore, RNF113A promoted BRR2 binding to ASCC2, which was dependent on its RING domain (Extended Data Fig. 10d ). Recombinant BRR2 was ubiquitinated in vitro by RNF113A, also in a manner dependent on its RING domain (Extended Data Fig. 10e) . Knockdown of BRR2, or its partner PRP8 (ref. 16 ), significantly reduced ASCC3 foci formation upon MMS damage (Extended Data Fig. 10f, g and Fig. 4f) . Consistently, loss of BRR2 increased sensitivity to MMS (Extended Data Fig. 10h ). Thus, BRR2 probably represents at least one physiological substrate for RNF113A in this alkylation repair pathway.
Our results provide the first evidence for an alkylation-specific damage response in human cells. The ASCC complex acts as a major node in this pathway, sensing ubiquitin-dependent signalling (via ASCC2) and concomitantly recruiting alkylation repair enzymes (ALKBH3 and ASCC3). As such, ASCC2 serves as an adaptor, and may be analogous to Rap80, which recruits the BRCA1 complex to chromatin during the double-stranded break response 1 . Indeed, Rap80 recognizes non-proteosomal ubiquitin chains produced by the upstream RNF8/RNF168 E3 ubiquitin ligases before BRCA1 recruitment. Here, RNF113A functions as the E3 ligase to transduce the alkylation damage signal. How alkylation damage uniquely activates RNF113A to recruit ASCC2 versus other repair complexes will be an important question for future studies. RNF113A contains a CCCH-type zinc finger, a motif known to bind RNA. Since RNA is also modified by exposure to alkylating agents, it is possible that damaged RNA serves as the initial signal to activate DNA alkylation repair. As our work strongly suggests the presence of a cellular sensor specific for alkylation damage in human cells, it may be possible to target this pathway to improve tumour responses to conventional chemotherapy. Future studies will undoubtedly clarify these questions about the upstream signals for this novel damage signalling pathway.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Plasmids. Human ALKBH3, ASCC2, ASCC3, RNF113A, BRR2, and gp78 cDNAs were isolated as previously described 7 . For mammalian cell expression, cDNAs were subcloned into pHAGE-CMV-3×HA, pHAGE-CMV-Flag, or pMSCVFlag-HA as needed by Gateway recombination 19 . The cDNA for PCNA (a gift from Z. You, Washington University) was subcloned into pHAGE-CMV-GFP. For recombinant protein expression, cDNAs were subcloned into pGEX-4T1, pET28a-Flag, or pDEST10. All constructs derived by PCR, including deletions and point mutations, were confirmed by Sanger sequencing. Cell culture and cell survival assays. U2OS, PC-3, HeLa-S, and HEK293T cells (originally from the American Type Culture Collection) were cultured and maintained as previously described 20 . Cells were tested for mycoplasma at the Washington University Genome Engineering and iPSC Center, and were authenticated using the ATCC human STR profiling services. Normal and X-TTD patient lymphoblastoid cell lines were gifts from M. Corbett and J. Gecz (University of Adelaide). These cells were originally obtained after informed consent and ethical approval from the Women's and Children's Health Network Human Research Ethics Committee, as described 17 . They were maintained in RPMI 1640 media supplemented with 10% FBS and 1% penicillin-streptomycin 17 . Preparations of viruses, transfection, and viral transduction were performed as described previously 20 . For rescue experiments of knockout cell foci cells were transduced with the pHAGE-CMV-3xHA or pHAGE-CMV-Flag lentiviral rescue vector. For rescue experiments of knockout-cell MMS sensitivity, cells were transduced with the pMSCV-Flag-HA retroviral rescue vector. For survival assays of DNA damaging agent using PC-3 cells, 10,000 cells per well were cultured overnight in 96-well plates in 100 μ l media. Cells were then exposed to medium containing the indicated concentration of MMS (Sigma) for 24 h at 37 °C. The media were then replaced with normal media, and cell viability was assessed using the MTS assay (Promega) 72 h after initial damaging agent exposure. For experiments involving camptothecin, or bleomycin (both purchased from Sigma), cells were exposed to medium containing the indicated concentration of the damaging agent in culture medium for 72 h at 37 °C. Viability was then processed by MTS assay as above. For survival assays using the patient-derived cells, 10,000 cells were plated in 80 μ l of media. MMS-containing media were then added for a total volume of 100 μ l at the indicated final concentration of MMS and incubated for 72 h at 37 °C. The MTS assay was then performed as above. All MTS-based survival experiments were done in quintuplicate. CRISPR-Cas9-mediated knockouts. U2OS and PC-3 knockout cells were created using CRISPR-Cas9 genome editing at the Genome Engineering and iPSC Center (GEiC) at Washington University School of Medicine (St. Louis, Missouri, USA). PC-3 ASCC2 and ASCC3 knockout clones were initially assessed by deep sequencing and confirmed by western analysis. All other knockout clones were isolated and confirmed by western analysis. The gRNA sequences used to generate the knockout cell line were as follows: ASCC2, 5′-GCCAAGTTACTACAGTGACCTGG-3′ ; ASCC3, 5′-ATGGCTTTACCTCGTCTCACAGG-3′. Immunofluorescence microscopy. All immunofluorescence microscopy was performed as previously described 20 , with minor modifications. After treatment with the indicated damaging agent in complete medium at 37 °C for 6 h (500 μ M MMS, unless indicated otherwise; 1 μ M camptothecin; 10 mM hydroxyurea; 20 μ M bleomycin; 5 Gy IR; or 25 J m −2 ultraviolet light), U2OS cells were extracted with 1× PBS containing 0.2% Triton X-100 and protease inhibitors (Pierce) for 10-20 min on ice before fixation with 3.2% paraformaldehyde. The cells were then washed extensively with immunofluorescence wash buffer (1× PBS, 0.5% NP-40, and 0.02% NaN 3 ), then blocked with immunofluorescence blocking buffer (immunofluorescence wash buffer plus 10% FBS) for at least 30 min. Primary antibodies were diluted in immunofluorescence blocking buffer overnight at 4 °C. After staining with secondary antibodies (conjugated with Alexa Fluor 488 or 594; Millipore) and Hoechst 33342 (Sigma-Aldrich), where indicated, samples were mounted using Prolong Gold mounting medium (Invitrogen). Epifluorescence microscopy was performed on an Olympus fluorescence microscope (BX-53) using an ApoN 60× /1.49 numerical aperture oil immersion lens or an UPlanS-Apo 100× /1.4 numerical aperture oil immersion lens and cellSens Dimension software. Raw images were exported into Adobe Photoshop, and for any adjustments in image contrast or brightness, the levels function was applied. For foci quantification, at least 100 cells were analysed in triplicate, unless otherwise indicated. Flow cytometry. Samples were prepared and flow cytometry was performed using a BrdU Flow Kit (BD Pharmingen) protocol with minor modifications. U2OS cells were transduced with pHAGE-CMV-Flag-ASCC2 lentivirus for 72 h, treated with MMS, washed with PBS, and extracted with Triton X-100 as for immunofluorescence. Cells were then fixed by resuspension in BD Cytofix/ Cytoperm Buffer and incubated on ice for 15 min. Samples were washed with 1× BD Perm/wash buffer, resuspended with Flag antibody diluted in 1× BD Perm/wash buffer, incubated at room temperature for 1 h, and washed again in the same buffer. Samples were resuspended in buffer containing Alexa Fluor 488-conjugated secondary antibody and incubated at room temperature for 20 min. Samples were washed and resuspended in staining buffer (1× PBS + 2% FBS) containing 7-aminoactinomycin D and processed by flow cytometry. All flow cytometry analysis was performed on a FACSCalibur Flow Cytometer using CellQuest software. Post-acquisition analysis used FlowJo software (Tree Star). Colony formation assay. Parental or knockout cells were trypsinized, counted, and plated at low density. After overnight incubation, the cells were treated with the indicated doses of MMS or camptothecin for 24 h in complete medium. The cells were incubated for 12-14 days, fixed, and stained with crystal violet. The experiment was performed in quadruplicate for each cell line and drug dose. Colonies were counted and relative survival was normalized to untreated controls. In situ PLA. PLA was performed using a Duolink detection kit (Sigma) following the manufacturer's instructions with minor modifications. U2OS cells were extracted and fixed as described above. The cells were washed extensively with immunofluorescence wash buffer, then blocked with 1× Duolink blocking solution for 30 min at 37 °C in a pre-warmed humidifier. Primary antibodies were diluted in 1× Duolink antibody diluent and added to samples overnight at 4 °C. Samples were washed with wash buffer A at room temperature. PLA probes anti-rabbit PLUS and anti-mouse MINUS were diluted 1:5 in 1× Duolink antibody diluent, then added to samples and incubated for 1 h at 37 °C. Samples were again washed with wash buffer A at room temperature. Duolink ligation stock and ligase were diluted 1:5 and 1:40 in pure water, respectively, and applied to samples for 30 min at 37 °C. After washing with wash buffer A, Duolink amplification red probe and polymerase were diluted 1:5 and 1:80 in water and applied to samples for 100 min at 37 °C. After a brief wash with wash buffer B, samples were mounted using Duolink mounting medium with DAPI and imaged as above.
Purification of TAP-ASCC2 complexes and MS/MS analysis.
Affinity purification of ASCC2 was performed as previously described for ALKBH3, with minor modifications 7 . Briefly, Flag-HA-ASCC2 was stably expressed after transduction of pMSCV-Flag-HA-ASCC2 retrovirus into HeLa-S cells. Nuclear extract was prepared from the stable cell line with or without previous treatment with MMS (400 μ M for 6 h), and the ASCC2 complex was purified using anti-Flag (M2) resin (Sigma), followed by purification using anti-HA (F-7) resin (Santa Cruz) in TAP buffer (50 mM Tris-HCl pH 7.9, 100 mM KCl, 5 mM MgCl 2 , 10% glycerol, 0.1% NP-40, 1 mM DTT, and protease inhibitors). For comparison of wild-type ASCC2 versus ASCC2 L506A, the same method was used, except that both samples were treated with MMS and the HA purification was omitted. After peptide elution, the complexes were TCA precipitated and associated proteins were identified by LC-MS/MS at the Taplin Mass Spectrometry Facility (Harvard Medical School, Boston, Massachusetts, USA) using an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (ThermoFisher) and Sequest software 21 . Protein purification. Recombinant proteins (ALKBH3, ASCC2, ASCC3, and gp78 CUE) were purified from Rosetta (DE3) or Sf9 cells using an ÄKTA-pure FPLC (GE Healthcare). For His-tagged bacterially expressed proteins, cells were resuspended in His-lysis buffer (50 mM Tris-HCl pH 7.3, 250 mM NaCl, 0.05% Triton X-100, 3 mM β − ME, 30 mM imidazole, and protease inhibitors) and lysed by sonication. After centrifugation and filtration, the extract was loaded onto a HisTrap HP column using a 50 ml Superloop (GE Healthcare). After extensive washing with lysis buffer, the protein was eluted using lysis buffer containing 400 mM imidazole. His-Flag-ALKBH3 was further purified on a Superdex 200 Increase 10/300 GL size-exclusion column. All recombinant proteins were dialysed into TAP buffer. Flag-tagged RNF113A was purified from HeLa-S cells by resuspension in Flag-lysis buffer (50 mM Tris-HCl pH 7.9, 150 mM NaCl, 10% glycerol 1.0% Triton X-100, 1 mM DTT, and protease inhibitors) and lysed by sonication. After incubation with Flag resin, the protein was eluted with lysis buffer containing 0.4 mg ml −1 Flag peptide. Protein and RNA binding assays. All in vitro binding assays were performed as previously described 4 , with minor modifications. Flag (M2) agarose and Ni-NTA agarose beads were pre-blocked with 10% bovine serum albumin. For ubiquitin binding assays, 10 μ g of His-ASCC2 or His-ASCC2 mutants were added to each reaction, along with 500 ng of either K48-or K63-Ub 2-7 (Boston Biochem). The indicated proteins were added to 10 μ l of beads in a total volume of 100 μ l with TAP wash buffer. Reactions were incubated at 4 °C with rotation for 1 h, then washed extensively with TAP wash buffer. A final wash was performed with 1× PBS, and bound material was eluted with 20 μ l of Laemmli buffer, analysed by SDS-PAGE, and stained with Coomassie blue or subjected to western analysis as indicated. For RNA binding experiments, 0.5 nmol of each 5′ -biotinylated RNA (50-mer sequence: 5′ -UCGAUAGUCUCUAGACAGCAUGUCCUAG CAAGCCAGAAUUCGGCAGCGUC-3′ ; the 35-mer and 20-mer removed 15 and Letter reSeArCH 30 nucleotides from the 3′ end of the same sequence, respectively) was immobilized on 10 μ l streptavidin-agarose beads. To each reaction, 1 μ g of His-NΔ -ASCC3 (residues 401-2202) was added in a total volume of 100 μ l in TAP wash buffer with RNase inhibitor (NEB). Reactions were incubated at 25 °C with rotation for 30 min, then washed extensively with TAP wash buffer. A final wash was performed with 1× PBS, and bound material was eluted with 10 μ l of Laemmli buffer, analysed by SDS-PAGE and western blotting. Ubiquitin ligase assays. Reactions analysing ubiquitin chain polymerization were performed in ubiquitin ligase buffer (25 mM Tris pH 7.3, 25 mM NaCl, 10 mM MgCl 2 , 100 nM ZnCl, 1 mM mercaptoethanol) containing 5 mM ATP and 100 μ M of either wild-type ubiquitin or K63R ubiquitin in a total volume of 20 μ l. E1 activating enzyme (UBE1; Boston Biochem) was used at 500 nM, and E2 ubiquitin conjugating enzymes (Ubch5c or Ubc13/MMS2; Boston Biochem) were added at the indicated concentrations. Flag-HA-tagged-RNF113A or RNF113A I264A mutant protein purified from HeLa-S cells was added to each reaction and incubated at 37 °C for 3 h. Reactions were stopped with 20 μ l of Laemmli buffer, analysed by SDS-PAGE, and western blotted. For ubiquitination of BRR2, 1 μ g of His-NΔ -BRR2 (residues 394-2136) purified from Sf9 cells was used as a substrate for ubiquitination with Flag-RNF113A (wild-type and Δ RING) purified from HeLa cells. Each reaction contained E1 (50 nM), E2 (Ubch5c; 150 nM), 2 μ g HA-Ub, and 2 mM ATP, and were incubated at 35 °C for 2 h. An aliquot (5 μ l) of the total E3 reaction was saved, and the remaining reaction was used for binding to Ni-NTA beads for 1 h. After extensive washing with TAP buffer, the captured His-BRR2 was eluted with Laemmli buffer, analysed by SDS-PAGE, and western blotted. Immunoprecipitation. Immunoprecipitation of HA-tagged RNF113A was performed by transient expression in HEK293T cells. The cells were resuspended in high-salt buffer (50 mM Tris-HCl pH 7.9, 300 mM NaCl, 10% glycerol, 1.0% Triton X-100, 1 mM DTT, and protease inhibitors), lysed by sonication, and centrifuged. An equal volume of buffer containing no salt was added, and the lysate was incubated with anti-HA resin. After incubation at 4 °C with rotation, the beads were washed extensively with buffer containing 150 mM NaCl. Bound material was eluted with Laemmli buffer and analysed by SDS-PAGE. Immunoprecipitation after denaturation was performed as previously described 19 with minor modifications. Briefly, HEK293T cells were transfected with His-Ub, then transduced with the indicated shRNA lentivirus. Cells were then treated with 500 μ M MMS for 6 h and harvested. Pellets were resuspended in TBS + 1% SDS and further lysed by sonication, boiled, and cleared by centrifugation. Samples were diluted to 0.1% SDS with lysis buffer (50 mM Tris pH 7.9, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM DTT, and protease inhibitors) and incubated with Ni-NTA beads at 4 °C overnight. After incubation and extensive washing with lysis buffer, the bound material was eluted with Laemmli buffer and analysed by western blotting. Isothermal titration calorimetry. All reported isothermal titration calorimetry data were collected using a MicroCal iTC 200 instrument. His-tagged ASCC2, the L506A ASCC2 mutant, and K63-Ub 2 were dialysed in 20 mM HEPES pH 7.5, 150 mM NaCl, and 200 μ M tris(2-carboxyethyl)phosphine before the experiment. For the wild-type ASCC2 binding experiment, a 102 μ M K63-Ub 2 solution in the sample cell was titrated with 435 μ M ASCC2 solution using eighteen 2-μ l injections. The L506A ASCC2 binding experiment was performed similarly, with 388 μ M L506A ASCC2 titrated into 42 μ M K63-Ub 2 . Fitting was performed using Origin 7 SR4 (OriginLab). Structural analysis. PyMOL (the PyMOL Molecular Graphics System, version 1.8.0.5 Schrödinger) was used to align the structure of ASCC2 residues 463-525 (PDB accession number 2DI0) with the VSP9 CUE:ubiquitin complex structure (PDB accession number 1P3Q). Figure 2c and Extended Data Fig. 3E were generated using PyMOL.
Quantification of methylated bases using LC-MS/MS. Cells were grown in DMEM (Sigma-Aldrich), supplemented with 0.03 g l −1 triple-deuterized l-methionine (Sigma-Aldrich), for at least five cell divisions before the experiment. For each condition, three 10-cm cell culture dishes were used. MMS was added to the growth medium at a final concentration of 1 mM and cells incubated further for 1 h. After a brief wash with pre-warmed PBS, new medium was added and the cells incubated further for various time spans before analysis. After medium removal, culture plates (60-80% confluency) were placed on ice and washed with ice-cold PBS. Cells were harvested by scraping into ice-cold PBS, centrifuged and the pellet washed with ice-cold PBS. Dry pellets were snap frozen and stored at − 80 °C until further processing. Cell lysis and total DNA isolation was performed with an AllPrep DNA/RNA/Protein Mini kit (Qiagen) according to the manufacturer's instructions. DNA was hydrolysed to nucleosides by 20 U benzonase (Santa Cruz), 0.2 U nuclease P1, and 0.1 U alkaline phosphatase (Sigma) in 10 mM ammonium acetate, pH 6.0, and 1 mM magnesium chloride at 40 °C for 40 min. Three volumes of acetonitrile was added and the sample was centrifuged (16,000g, 30 min, 4 °C). The supernatants were dried and dissolved in 50 μ l water for LC-MS/MS analysis of methylated and unmodified nucleosides. Chromatographic separation was performed using an Agilent 1290 Infinity II UHPLC system with a ZORBAX RRHD Eclipse Plus C18 150 × 2.1 mm internal diameter (1.8 μ m) column protected with an ZORBAX RRHD Eclipse Plus C18 5 × 2.1 mm internal diameter (1.8 μ m) guard column (Agilent). The mobile phase consisted of water and methanol (with 0.1% formic acid) run at 0.25 ml min Table 2 . For the screen, U2OS cells were concurrently transduced with pHAGE-CMV-3xHA-ASCC2 lentivirus and individual lentiviral shRNAs. A scrambled pLKO.1 shRNA and a lentivirus targeting UBC13 (TRCN0000039435) served as the negative and positive controls, respectively. After approximately 72 h, the cells were treated with MMS (500 μ M) for 6 h and processed for immunofluorescence microscopy using anti-HA and pH2A.X. At least 100 cells per sample were analysed for HA-ASCC2 foci formation. Quantified results were normalized to the scrambled control. RNF113A was the only candidate E3 ligase with three independent shRNAs exhibiting at least a threefold reduction in MMS-induced HA-ASCC2 foci formation. For verification, U2OS cells were co-transduced with pHAGE-CMV-3xHA-ASCC2 and the candidate lentiviral shRNAs. HA-ASCC2 foci formation was assessed as above. Statistical analyses. All P values were calculated by unpaired, two-tailed Student's t-test. All error bars represent the standard deviation, unless otherwise noted. Antibodies. All antibodies for this study are shown in Supplementary Table 4 
Data exclusions
Describe any data exclusions. No data were excluded from the analysis.
Replication
Describe whether the experimental findings were reliably reproduced. All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization does not apply to our study, as we are following biochemical or cell biological phenomena.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were blinded to group allocation during the collection of foci image data.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
No code was used for the study
